Keywords: daiichi, sankyo, takes, japanese, rights, cs-8958, lani
Daiichi Sankyo takes on Japanese rights to CS-8958, a LANI co-developed with Biota
Article | 02 April 2009
Australia's Biota Holdings says that Daiichi Sankyo, the co-owner of the long-acting neuraminidase inhibitor CS-8958, has signed a contract to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
